These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 29317080)

  • 1. Effective regeneration of dystrophic muscle using autologous iPSC-derived progenitors with CRISPR-Cas9 mediated precise correction.
    Hagan M; Ashraf M; Kim IM; Weintraub NL; Tang Y
    Med Hypotheses; 2018 Jan; 110():97-100. PubMed ID: 29317080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors.
    Jin Y; Shen Y; Su X; Weintraub N; Tang Y
    J Vis Exp; 2019 Sep; (151):. PubMed ID: 31566614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective restoration of dystrophin expression in iPSC
    Jin Y; Shen Y; Su X; Weintraub NL; Tang Y
    Comput Struct Biotechnol J; 2020; 18():765-773. PubMed ID: 32280431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel CRISPR-Cas9 Strategy to Target DYSTROPHIN Mutations Downstream of Exon 44 in Patient-Specific DMD iPSCs.
    Dhoke NR; Kim H; Azzag K; Crist SB; Kiley J; Perlingeiro RCR
    Cells; 2024 Jun; 13(11):. PubMed ID: 38891104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR/Cas9-Based Dystrophin Restoration Reveals a Novel Role for Dystrophin in Bioenergetics and Stress Resistance of Muscle Progenitors.
    Matre PR; Mu X; Wu J; Danila D; Hall MA; Kolonin MG; Darabi R; Huard J
    Stem Cells; 2019 Dec; 37(12):1615-1628. PubMed ID: 31574188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR/Cas9 editing of directly reprogrammed myogenic progenitors restores dystrophin expression in a mouse model of muscular dystrophy.
    Domenig SA; Bundschuh N; Lenardič A; Ghosh A; Kim I; Qabrati X; D'Hulst G; Bar-Nur O
    Stem Cell Reports; 2022 Feb; 17(2):321-336. PubMed ID: 34995499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle Cells.
    Young CS; Hicks MR; Ermolova NV; Nakano H; Jan M; Younesi S; Karumbayaram S; Kumagai-Cresse C; Wang D; Zack JA; Kohn DB; Nakano A; Nelson SF; Miceli MC; Spencer MJ; Pyle AD
    Cell Stem Cell; 2016 Apr; 18(4):533-40. PubMed ID: 26877224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Creation of a Novel Humanized Dystrophic Mouse Model of Duchenne Muscular Dystrophy and Application of a CRISPR/Cas9 Gene Editing Therapy.
    Young CS; Mokhonova E; Quinonez M; Pyle AD; Spencer MJ
    J Neuromuscul Dis; 2017; 4(2):139-145. PubMed ID: 28505980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel rabbit model of Duchenne muscular dystrophy generated by CRISPR/Cas9.
    Sui T; Lau YS; Liu D; Liu T; Xu L; Gao Y; Lai L; Li Z; Han R
    Dis Model Mech; 2018 Jun; 11(6):. PubMed ID: 29871865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9.
    Li HL; Fujimoto N; Sasakawa N; Shirai S; Ohkame T; Sakuma T; Tanaka M; Amano N; Watanabe A; Sakurai H; Yamamoto T; Yamanaka S; Hotta A
    Stem Cell Reports; 2015 Jan; 4(1):143-154. PubMed ID: 25434822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR technologies for the treatment of Duchenne muscular dystrophy.
    Choi E; Koo T
    Mol Ther; 2021 Nov; 29(11):3179-3191. PubMed ID: 33823301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The AAV-mediated and RNA-guided CRISPR/Cas9 system for gene therapy of DMD and BMD.
    Wang JZ; Wu P; Shi ZM; Xu YL; Liu ZJ
    Brain Dev; 2017 Aug; 39(7):547-556. PubMed ID: 28390761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy.
    Happi Mbakam C; Lamothe G; Tremblay G; Tremblay JP
    Neurotherapeutics; 2022 Apr; 19(3):931-941. PubMed ID: 35165856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR Therapeutics for Duchenne Muscular Dystrophy.
    Erkut E; Yokota T
    Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Production of Duchenne muscular dystrophy cellular model using CRISPR-Cas9 exon deletion strategy.
    Alizadeh F; Abraghan YJ; Farrokhi S; Yousefi Y; Mirahmadi Y; Eslahi A; Mojarrad M
    Mol Cell Biochem; 2024 May; 479(5):1027-1040. PubMed ID: 37289342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR-mediated correction of skeletal muscle Ca
    Morera C; Kim J; Paredes-Redondo A; Nobles M; Rybin D; Moccia R; Kowala A; Meng J; Garren S; Liu P; Morgan JE; Muntoni F; Christoforou N; Owens J; Tinker A; Lin YY
    Neuromuscul Disord; 2022 Dec; 32(11-12):908-922. PubMed ID: 36418198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR-Cas9 Correction of Duchenne Muscular Dystrophy in Mice by a Self-Complementary AAV Delivery System.
    Zhang Y; Bassel-Duby R; Olson EN
    Methods Mol Biol; 2023; 2587():411-425. PubMed ID: 36401041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Creation of DMD Muscle Cell Model Using CRISPR-Cas9 Genome Editing to Test the Efficacy of Antisense-Mediated Exon Skipping.
    Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():165-171. PubMed ID: 30171541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restoration of dystrophin expression and correction of Duchenne muscular dystrophy by genome editing.
    Aslesh T; Erkut E; Yokota T
    Expert Opin Biol Ther; 2021 Aug; 21(8):1049-1061. PubMed ID: 33401973
    [No Abstract]   [Full Text] [Related]  

  • 20. Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA.
    Long C; McAnally JR; Shelton JM; Mireault AA; Bassel-Duby R; Olson EN
    Science; 2014 Sep; 345(6201):1184-1188. PubMed ID: 25123483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.